← Back to Search
Effects Of GH Replacement On Metabolism And Physical Performance In GH Deficient Adults
S. K. Abdul Shakoor, S. Shalet
Published 2003 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
GH deficiency (GHD) in adults is associated with abnormalities in body composition, metabolic derangements, sub-optimal physical performance, high incidence of adverse cardiovascular risk factors and poor quality of life. GHD adults are insulin resistant and have reduced hepatic glycogen stores, reduced insulin stimulated glucose utilization and reduced glycogen synthesis in muscle. GH replacement results in either no change or slight reduction in insulin sensitivity. Hence, it is important to monitor for the development of glucose intolerance in patients on long-term GH replacement. GHD is associated with a lipid profile known to predispose to premature atherosclerosis and cardiovascular disease, i.e. increased total and LDL cholesterol, decreased HDL cholesterol, increased small dense LDL particles and increased triglycerides. LDL-cholesterol abnormalities appear to improve with GH replacement even if maintained within physiological dose range; the greatest improvement occurs in those subjects with higher baseline total and LDL cholesterol values and in female patients with adult onset GHD compared with male patients with childhood onset GHD. In contrast, hypertriglyceridaemia is not corrected by GH replacement. The majority of the reports suggest GH replacement increases Lipoprotein-a levels. Long-term observation will be required to determine whether GH replacement reduces cardiovascular morbidity and mortality in GHD adults. The reduced muscle mass and strength associated with GHD has been shown to improve after GH replacement. GH treatment also improves maximal and sub-maximal exercise performance in GHD adults. The effects on protein metabolism, energy expenditure and thyroid metabolism in GHD adults are also critical.
This paper references
Insulin-like growth factor I stimulates human erythroid colony formation in vitro.
M. Claustres (1987)
Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency.
R. Cuneo (1993)
Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency.
Y. J. Janssen (1999)
Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience.
C. Hwu (1997)
Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.
M. Christopher (1998)
Body composition and energy expenditure in acromegaly.
A. O'Sullivan (1994)
Continuation of growth hormone (GH) substitution during fasting in GH-deficient patients decreases urea excretion and conserves protein synthesis.
H. Nørrelund (2001)
Changes in lipoprotein (a) levels measured by six kit methods during growth hormone treatment of growth hormone deficient adults
Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition
J. Jørgensen (1996)
Growth hormone-deficient adults are insulin-resistant.
J. Johansson (1995)
The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients.
J. Gibney (1999)
Exercise capacity and hormonal response in adults with childhood onset growth hormone deficiency during long-term somatropin treatment.
L. Gullestad (1998)
Effects of 7 years of growth hormone replacement therapy in hypopituitary adults.
A. Chrisoulidou (2000)
Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group.
A. Attanasio (1997)
Whole-body leucine turnover in adults on conventional treatment for hypopituitarism.
S. Beshyah (1993)
Resting metabolic rate, body composition and related hormonal parameters in growth hormone-deficient adults before and after growth hormone replacement therapy.
Y. E. Snel (1995)
Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study
D. Florakis (2000)
The growth hormone deficiency syndrome in adults
R. Cuneo (1992)
The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis.
D. O'Neal (1994)
Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement.
G. Leese (1999)
Effects of growth hormone administration on fuel oxidation and thyroid function in normal man.
J. Møller (1992)
The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
R. Cuneo (1998)
Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength.
R. Cuneo (1991)
Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose‐dependent manner and suppresses circadian thyrotrophin levels: studies in GH‐deficient adults
J. O. L. Jørgensen (1994)
Effect of human growth hormone and insulin-like growth factor I on whole-body leucine and estimates of protein metabolism.
M. Haymond (1993)
Energy expenditure and body composition in growth hormone deficient adults on exogenous growth hormone
P. K. Chong (1994)
The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition
A. Binnerts (1992)
Fasting and postprandial lipid abnormalities in hypopituitary women receiving conventional replacement therapy.
K. Al-Shoumer (1997)
Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)
Z. Laron (1997)
Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans.
D. Fryburg (1991)
Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study.
E. Christ (1999)
The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults.
A. Rosenfalck (2000)
How is whole body protein turnover perturbed in growth hormone-deficient adults?
D. M. Hoffman (1998)
Low‐dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome
R. Murray (2002)
The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults.
J. Weaver (1995)
Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance.
J. Jørgensen (1994)
A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults.
P. Lucidi (1998)
Pituitary control of lipoprotein and bile acid metabolism in male rats: growth hormone effects are not mediated by prolactin.
M. Matasconi (2004)
The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency.
F. Salomon (1989)
Growth Hormone Treatment in Adults with Growth Hormone Deficiency: Effect on Muscle Fibre Size and Proportions
H. Whitehead (1989)
Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapy.
D. O'Neal (1996)
Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement.
A. Cittadini (1994)
The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance.
S. Beshyah (1995)
Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance.
R. Cuneo (1991)
Recombinant human insulin‐like growth factor‐I decreases serum lipoprotein(a) concentrations in normal adult men
J. Oscarsson (1995)
The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy.
D. O’Neal (1999)
Calorigenic effects of growth hormone: the role of thyroid hormones.
T. Wolthers (1996)
Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity.
F. L. Hew (1996)
The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients
D. Russell‐Jones (1994)
Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency.
J. Fowelin (1993)
The effects of growth hormone on protein metabolism in adult growth hormone deficient patients
D. Russell-Jones (1993)
Skeletal muscle performance in adults with growth hormone deficiency.
R. Cuneo (1990)
Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7alpha-hydroxylase in the rat.
M. Rudling (1997)
Serum lipid levels in growth hormone-deficient men.
H. D. de Boer (1994)
Glucose and fat metabolism in adults with growth hormone deficiency
F. Salomon (1994)
Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults.
L. Woodhouse (1999)
A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF‐I without significant deterioration in glucose tolerance
B. Bülow (1999)
The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone-deficient adults.
J. Webster (1997)
Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood.
R. Nass (1995)
This paper is referenced by
Obesity is a sign – over‐eating is a symptom: an aetiological framework for the assessment and management of obesity
A. Sharma (2010)
GH and IGF1 levels are positively associated with musculotendinous collagen expression: experiments in acromegalic and GH deficiency patients.
S. Doessing (2010)
Acromegaly and aging: a comparative cross-sectional study.
E. Hatipoğlu (2015)
Hormonal and Chemical Regulation of Paraoxonases in Mice
X. Cheng (2012)
High prevalence of coronary calcifications and increased risk for coronary heart disease in adults with growth hormone deficiency
S. Cannavó (2011)
Dietary protein in the regulation of the somatotropic axis
J.A.H. van Vught (2009)
Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency.
C. Høybye (2007)
Diagnostic in Obesity and Complications Obesity is a sign – over-eating is a symptom: an aetiological framework for the assessment and management of obesityobr_689 362..370
A. M. Sharma (2010)
Growth hormone 1 (GH1) gene and performance and post-race rectal temperature during the South African Ironman triathlon
B. Walpole (2006)
Metabolic co-morbidities revealed in patients with childhood-onset adult GH deficiency after cessation of GH replacement therapy for short stature.
I. Fukuda (2008)
Adipokine protein expression pattern in growth hormone deficiency predisposes to the increased fat cell size and the whole body metabolic derangements.
J. Ukropec (2008)
ORIGINAL ARTICLE: Metabolic outcome of GH treatment in prepubertal short children with and without classical GH deficiency
R. Decker (2010)
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index.
G. Corneli (2005)
Lactate dehydrogenase regulation in aged skeletal muscle: Regulation by anabolic steroids and functional overload
T. Washington (2014)
Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study.
U. Plöckinger (2008)
HDL cholesterol and bone mineral density: is there a genetic link?
C. Ackert-Bicknell (2012)
Smallness for gestational age is associated with persistent change in insulin-like growth factor I (IGF-I) and the ratio of IGF-I/IGF-binding protein-3 in adulthood.
R. Verkauskienė (2005)
Exercise and Protein Metabolism
M. D. Pasquale (2007)
Derangements Predisposes to the Increased Fat Cell Size and the Whole Body Metabolic Adipokine Protein Expression Pattern in Growth Hormone Deficiency
J. Eckel (2008)
Long-Term Efficacy and Safety of Two Doses of Growth Hormone in Short Japanese Children Born Small for Gestational Age
T. Tanaka (2011)
Long-Term Challenges in Growth Hormone Treatment
A. L. Cerro (2004)